SAFETY AND TOLERABILITY

Ascendis Pharma · Navepegritide · TransCon CNP

FDA Accepts TransCon® CNP NDA for Priority Review

SOURCE: Investors.AscendisPharma.com (June 2, 2025) – Once-weekly TransCon CNP demonstrated significantly higher annualized growth velocity, the primary endpoint, compared to placebo – Multiple benefits beyond linear growth were observed compared…

Read More FDA Accepts TransCon® CNP NDA for Priority Review
Ascendis Pharma · Navepegritide · TransCon CNP

New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)

SOURCE: Investors.AscendisPharma.com COPENHAGEN, Denmark, May 13, 2025 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced new data showing improvements in growth and bone morphometry from Week 52 of its pivotal ApproaCH Trial…

Read More New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)

translate ?